Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CCR Translations

Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient

David A. Mankoff, Lisa K. Dunnwald, Savannah C. Partridge and Jennifer M. Specht
David A. Mankoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa K. Dunnwald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savannah C. Partridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer M. Specht
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-09-1448 Published September 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Diagram of quantitative imaging methods used to measure blood flow and metabolism. Native molecules are shown in black lettering, and administered radiopharmaceuticals are shown in red. The delivery of nutrients and oxygen is dependent upon tissue perfusion or blood flow. 15O-water is a freely diffusible substance whose delivery is limited by blood flow. Dynamic 15O-water captures the time course of tracer uptake and washout in tissue, from which regional tissue perfusion can be estimated. FDG is a glucose analog that traces glycolysis. After delivery by blood flow and transit across capillaries and cellular membranes, FDG is phosphorylated inside the cell by hexokinase (HK), the rate-limiting step in glycolysis; but FDG is not a substrate for downstream steps in glycolysis. FDG, therefore, is “metabolically trapped” as FDG-6P, at a rate proportional to the glucose metabolic flux. Sequential injections of 15O-water (t1/2 ≈ 2 minutes) and 18F-FDG (t1/2 ≈ 2 hours) can yield regional estimates of tissue blood flow and glucose metabolism, and the ratio between flow and metabolism.

Additional Files

  • Figures
  • Related Article

    This CCR Translation refers to the following article:
    Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness
    Gaber Komar, Saila Kauhanen, Kaisa Liukko, Marko Sepp�nen, Sami Kajander, Jari Ovaska, Pirjo Nuutila, and Heikki Minn

    PreviousNext
    Back to top
    Clinical Cancer Research: 15 (17)
    September 2009
    Volume 15, Issue 17
    • Table of Contents
    • Table of Contents (PDF)
    • About the Cover

    Sign up for alerts

    View this article with LENS

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Clinical Cancer Research article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient
    (Your Name) has forwarded a page to you from Clinical Cancer Research
    (Your Name) thought you would be interested in this article in Clinical Cancer Research.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient
    David A. Mankoff, Lisa K. Dunnwald, Savannah C. Partridge and Jennifer M. Specht
    Clin Cancer Res September 1 2009 (15) (17) 5294-5296; DOI: 10.1158/1078-0432.CCR-09-1448

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient
    David A. Mankoff, Lisa K. Dunnwald, Savannah C. Partridge and Jennifer M. Specht
    Clin Cancer Res September 1 2009 (15) (17) 5294-5296; DOI: 10.1158/1078-0432.CCR-09-1448
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Disclosure of Potential Conflicts of Interest
      • Note in Proof
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • Biomarkers for oncolytic viruses
    • Inactivating BTK Mutations in Follicular Lymphoma
    • Blood biomarkers to enhance treatment selection
    Show more CCR Translations
    • Home
    • Alerts
    • Feedback
    • Privacy Policy
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts

    Info for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians

    About Clinical Cancer Research

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright © 2021 by the American Association for Cancer Research.

    Clinical Cancer Research
    eISSN: 1557-3265
    ISSN: 1078-0432

    Advertisement